https://www.cambridge.org/core/terms Downloaded from Proceedings of the Nutrition Society h uhr 03Frtpbihdoln 1Spebr2013 September 11 online published First 2013 Authors The © shei/eefso;L,ln hi;NP,Naahdnlpopaiy taoaie O ircoxide. nitric NO, ethanolamine; N-arachidonyl-phosphatidyl NAPE, * chain; long LC, ischaemia/reperfusion; reviews, Abbreviations: published have detailed topics recent these to of both subject of Since demonstrate been effects to (LC)-PUFA. vasculo-protective literature chain and extensive endocannabinoid Moreover, cardio- equally tissues. functioning the an cardiovascular is and within there active system an that (EC) demonstrating is literature substantial there a now is There Society Nutrition the of Proceedings orsodn author: Corresponding ofrneon Conference noanbni ytma oeta ehns for mechanism potential a as system Endocannabinoid https://www.cambridge.org/core oynauae at cdmdae adoaclrprotection cardiovascular mediated acid fatty polyunsaturated h urto oit ctihScinMeigwshl tPlakHls dnug n18 on Edinburgh Halls, Pollack at held was Meeting Section Scottish Society Nutrition The -G -rcioy lcrl E,aadmd;AI ct ycrilifrto;C,cnaiod C noanbni;I/R, endocannabinoid; EC, cannabinoid; CB, infarction; myocardial acute AMI, anandamide; AEA, glycerol; 2-arachidonyl 2-AG, nttt o elh&WlaeRsac,Rbr odnUiest,Aede,UK Aberdeen, University, Gordon Robert Research, Welfare & Health for Institute o hi nirhtmcefcs lhuhbt Cand EC both Although effects. antiarrhythmic their for iselvl fE hog omto fEC of formation that through EC shows of overwhelmingly levels literature tissue the cardio-protection, and h ramn n rvnino teoceoi n ycrilijr olwn ischae- for following approaches injury novel myocardial into and research atherosclerosis further of for prevention mia/reperfusion. avenue and fascinating treatment af a the greater of provides a effects EC the have mediate native conjugates may these EC that that discovery argument an to intuitive nuy hl lcaeo -yeCa L-type of blockade while injury, in of and hypertension inhibition EC in However, by that reduction. pressure unlikely com- blood is of indicate it anisms may available, bene that data any differences the mediate From and EC myocardial mechanisms. similarities integrated acute the or identify and mon to atherosclerosis attempts (hypertension, and disorders infarction) and cardiovascular EC major both three how of understanding current h usina owehro o Cmy tlati at lyarl nmdaigthe mediating in role a play part, in least at may, EC of not or effects vasculo-protective whether to cardio-and as question the L)PF.I snwbcmn vdn htteeapast eacoerelationship close a be to appears of there extensive that effects equally evident an vasculo-protective with is becoming and intervention are there now dietary they between Moreover, cardio- main, is states. the the It in CVD that, (LC)-PUFA. demonstrate various notion of to the support setting literature to (or the literature role substantial in pathophysiological or a cardiovas- protective physiological is within a there either system and has (EC) system both), endocannabinoid this that functioning implies and tissues active cular an of presence The . rfso hryL anrgt mi:[email protected] email: Wainwright, L. Cherry Professor https://doi.org/10.1017/S0029665113003406 ‘ Endocannabinoids: oynauae at cdmdaos mlctosfrhmnhealth human for implications mediators: acid fatty Polyunsaturated . IPaddress: ypsu :Cnaiod nhmnhealth human in Cannabinoids 3: Symposium n- CPF ntestigo ohahrslrssadmoada reperfusion myocardial and atherosclerosis both of setting the in LC-PUFA 3 (2013), hryL anrgt n iaMichel Lisa and Wainwright* L. Cherry 170.106.34.90 fi ilefcsof effects cial n 72 3L-UA teoceoi:Hpreso:Cardioprotection: Hypertension: Atherosclerosis: LC-PUFA: -3 460 , , on – n- 27 Sep2021 at07:50:31 6 doi:10.1017/S0029665113003406 469 long- 3 n- 2+ CPF n hne ntsu eeso C raising EC, of levels tissue in changes and LC-PUFA 3 n 3L-UA ic hyd o hr omnmech- common share not do they since LC-PUFA, -3 hnesi n ftepsil omnmechanisms common possible the of one is channels Arrhythmia n- CPF.Ti re eiwsmaie the summarises review brief This LC-PUFA. 3 n- – n- CPF xr hi rtcieefcsin effects protective their exert LC-PUFA 3 CPF ojgts hc scounter- is which conjugates, LC-PUFA 3 oprsn ewe h fet fteE and EC the draw to of attempt effects to therefore the is between review this comparisons intervention of dietary aim between The appears relationship there close with apparent, a becoming covered. be comprehensive now well to been a is previously present as have to However, that intended topics of not review is article this , subjectto theCambridgeCore termsofuse,available at fi iyfrcnaiodrcposta the than receptors cannabinoid for nity n- n- CPF n hne ntsu eeso EC. of levels tissue in changes and LC-PUFA 3 CPF eosrt vasculo- demonstrate LC-PUFA 3 fl n- maini nefc shared effect an is ammation CPF.Hwvr the However, LC-PUFA. 3 n- CPF decrease LC-PUFA 3 n- long-chain 3 n- – 9Mrh2013 March 19 long-chain 3 n- ’ 3 https://www.cambridge.org/core/terms Downloaded from Proceedings of the Nutrition Society n oai rvee in (reviewed virodhamine noladin and dopamine, N-arachidonoyl ethanolamide, ie -rti ope eetr r h CB the are receptors coupled G-protein nised h xsec fnnC eetrtreso h EC, the type-1 of vanilloid targets potential PPAR receptor receptor channels, non-CB transient of including suggests existence also studies the functional from evidence However, xrse rmrl nteprpey atclryby particularly periphery, the cells in immune primarily expressed anfcso hsrve.Hwvr ti otyof worthy receptor is CB identi it endogenous been However, additional have review. ligands various this that the of be and note therefore (AEA) focus will anandamide and main are (2-AG) which glycerol of 2-arachidonyl studied receptors, these most activate Indeed, the that factor. exist causative do a cardiovascular ligands as or endogenous response of processes stress a pathological part as in either participate as to to or responses either homoeostasis, mediate to ligands, there are endogenous they that implies tissue ntecnrlnrossse,btaeas located cardiac also including are tissues but system, peripheral nervous numerous central in the in nbt h myocardium the both in n h eetyd-rhnsdrcpo GPR55 receptor de-orphanised recently the and vascular receptors the syn- in reviewed their and (as controls degradation ligands and that thesis (EC) apparatus CB enzymatic associated endogenous (CB) their cannabinoid centrally receptors, The G-protein-coupled of variety processes. comprises signalling a physiological system in regulated endogenous role peripherally pivotal an and a plays constitutes that system system EC The a play LC-PUFA. may of EC effects not protective or the whether weigh in to around role and evidence CVD, the common of up setting the in LC-PUFA h eypeec fteercposi cardiovascular in receptors these of presence very The https://www.cambridge.org/core ( 6 ( , 2 7 , ) 3 ) ;CB n adipose and ( 3 h noanbni system endocannabinoid The ) aeas enrpre ob present be to reported been also have , ( 5 1 i.1. Fig. mn;pE,popoaadmd;NP-L,NP-eetv hshlps D; phospholipase NAPE-selective NAPE-PLD, phospho-anandamide; pAEA, PLA amine; ) h vascular the , eetr r rdmnnl expressed predominantly are receptors . 2 https://doi.org/10.1017/S0029665113003406 hshlps 2 L,popoiaeC. phospholipase PLC, A2; phospholipase , ytei ahasfraadmd AA.NAPE, (AEA). anandamide for pathways Synthetic fi ( ( 13 8 d nldn docosatetraenyl- including ed, ) ( ) 9 ). ise CB tissue. . IPaddress: ) noanbnisand Endocannabinoids n nohla cells endothelial and ‘ anandamide 170.106.34.90 ( 1 2 ) .Tetorecog- two The ). eetr,while receptors, ’ receptor , on 1 ( 12 n CB and 27 Sep2021 at07:50:31 ) . n 3ln-hi UAi adortcin461 cardioprotection in PUFA long-chain -3 ( ( 10 ( 4 11 , 5 ) ) 2 ) . IR nuy er failure heart injury, (I/R) eetv hshlps oyed2A (reviewed 2-AG lyso-phosphatidylinositol yield to a C sub- in by phospholipase and selective hydrolysis phosphatidylinositol sequent from phatidylinositol CB eeain(i hshlps A phospholipase (via generation eunl oAAtruhaCa a through AEA to sequently dacdatherosclerosis advanced hepatic A phospholipase identi (via 2-lyso-NAPE been to NAPE since have ( routes alternate However, aclrdysfunction vascular ism iad rvee in (reviewed ligands ntestigo he adoaclrdisorders, cardiovascular three the EC the review, of of this role setting potential of the the on purposes in focus the will pathological discussion between For widely varies conditions. detrimental) or tive speci ihref af higher higher marginally a with receptors, hshlpd,cnb yteie i i h pro- the (i) via via phosphatidylinositol C ( from synthesised phospholipase acid-containing diacylglycerol 2-AG be of arachidonic of duction from can synthesis generated phospholipids, The is hydrolysed AEA. further which is produce which phospho-AEA, to the yield to h CB the af n n iseE eesaerie navreyof variety a in raised are levels EC cerebral including pathologies, tissue cardiovascular-related and ing icllcrllps oyed2-AG yield to lipase diacylglycerol mn NP) i yrlsso AEb calcium a by NAPE of hydrolysis (Ca via (NAPE), amine precursor pholipid was AEA ( fi , subjectto theCambridgeCore termsofuse,available at 17 hr r o ueosrprsta ohcirculat- both that reports numerous now are There iyfrbt Brcposbthsahge ef higher a has but receptors CB both for nity 2 ( 2+ 15 ) .I em frcpo ciainb hs endogenous these by activation receptor of terms In ). fi eetr -G nteohrhn,hsasimilar a has hand, other the on 2-AG, receptor. ) estv,NP-eetv hshlps D phospholipase NAPE-selective sensitive, ) noanbni ytei n ie faction of sites and synthesis Endocannabinoid C n t rcs oe(..wehri sprotec- is it whether (i.e. role precise its and EC, c n lohdoyi fNP ypopoiaeC phospholipase by NAPE of hydrolysis also and , 2 ( 20 N eetrcmae oAEA. to compared receptor fi ) aahdnlpopaiy ethanol- -arachidonyl-phosphatidyl ayfrteCB the for cacy fi s hw ob yteie rmtephos- the from synthesised be to shown rst n myocardial and β N n usqethdoyi by hydrolysis subsequent and ( 18 aahdnlpopaiy ethanol- -arachidonyl-phosphatidyl ( 25 ) ,AAi ata gns tCB at agonist partial a is AEA ), ) oee,tentr fthe of nature the However, . ( 22 ( fi 24 d nldn ovrinof conversion including ed, ) 1 ) ibtccardiomyopathy diabetic , i.1 Fig. eetrcmae ihthe with compared receptor n bst-eae cardio- obesity-related and ( 21 ) 2+ fAAbiosynthesis AEA of ) ischaemia/reperfusion needn mechan- independent ( 16 fi 1 ) iyadmarkedly and nity flyso-phos- of ) n i)through (ii) and 2 n sub- and ) i.2 Fig. fi ayat cacy sn ( ( ( 23 19 14 1- ) ) ) ), , , . https://www.cambridge.org/core/terms Downloaded from Proceedings of the Nutrition Society ie seither as given Clvl,a dietary central on as effects the to levels, opposite picture the largely EC tissues be peripheral to in appears levels EC on LC-PUFA e rcnl eiwdin reviewed (recently tem ucin nihobtcadataryhi effects antiarrhythmic and in (reviewed antithrombotic mitochondrial function; cardiac improved pathways; signalling cell rlwrE ees Berger levels. not EC or lower whether or of terms in variable -Glvl nteban fmice of brains the that in levels shown 2-AG have studies de other trast, pnteE nqeto.I em fteefcsof effects the of terms In question. in EC the upon of fet.Ide,teei uligeiec finteractions of through evidence the building mechanisms between is there integrated Indeed, not effects. or the or both whether shared are to which EC as are of question levels the there in begs changes which which in observed, those to settings lar ilt,adti a ic enetne nsuisin studies in extended signi supplementation been in DHA since AEA where has of mice levels this brain and raising piglets, on ingestion LC-PUFA ouaino ada o hnes euto fTAG; of reduction channels; proposed in ion cardiac been of modulation have anti-in mechanisms including: underlying various E n -Glvl naioeadhattissue, heart and effect adipose anti-obesogenic an in with associated levels are that 2-AG both effects decreases and syndrome, metabolic AEA or feeding high-fat 462 e Crltdmtbltsi lsaadbrain and plasma in metabolites EC-related de a demonstrate to groups n acl-rtcieefcsof effects vasculo-protective signi and a is There myocar- acute I/R. dial and atherosclerosis hypertension, namely fi fl fi ilefcsof effects cial n- ec nmmrn irdmisaddownstream and microdomains membrane on uence inyicess hl upeetto decreases, supplementation while increases, ciency CPF nE eesapast edependent be to appears levels EC on LC-PUFA 3 https://www.cambridge.org/core neatosbtenlong-chain-PUFA between Interactions ( n- 26 – CPF n ciaino h Csys- EC the of activation and LC-PUFA 3 fi 29 hoil sh n- fi ) n- n endocannabinoids and atltrtr ocrigtecardio- the concerning literature cant fl CPF r bevdi eysimi- very in observed are LC-PUFA 3 .Wa sitrsigi htteben- the that is interesting is What ). CPF n h Ceettheir exert EC the and LC-PUFA 3 . maoyadat-xdn effects; anti-oxidant and ammatory https://doi.org/10.1017/S0029665113003406 i.2. Fig. hshtdlnstl A,daygyeo;PLA diacylglycerol; DAG, phosphatidylinositol; C-beta; ( 35 ) rkiloil krill or ( 30 n- . IPaddress: sn , 31 tal et ytei ahasfr2aahdnlgyeo 2A) yoP,lyso- Lyso-PI, (2-AG). glycerol 2-arachidonyl for pathways Synthetic -UAsupplementation, 3-PUFA -1-DAGL, ) lhuhthe although , ( 32 fi iieefc of effect nitive ) ( ( 36 170.106.34.90 34 n- eeoeo the of one were n- ) ) sn hsteimpact the Thus . CPF and LC-PUFA 3 nmdl feither of models in CPF raise LC-PUFA 3 1speci -1 n- fi atyaltered cantly LC-PUFA 3 , on .L anrgtadL Michel L. and Wainwright L. C. ( fi 33 fi dnsare ndings ) icllcrllipase. diacylglycerol c 27 Sep2021 at07:50:31 ncon- In . fi n- n- rst 3 3 1 hshlps A phospholipase , lo rsuei CB in pressure blood nsrietepsiiiyta ouaino h Csys- EC the of modulation by that tem possibility the raise ings mle htteCB the that implies hl eyhg ( high very while ogbe niseo otoes.Rcn nlssof studies analysis Recent epidemiological controversy. of and issue clinical an been long iy(n hscricotu)aogwt ietvaso- direct a with along output) effect. contracti- a cardiac dilator cardiac to thus at of lowering attributed (and suppression aimed been lity pressure tonic have system a hypertension blood of EC in combination The EC the of balance. of effects the up-regulation an redressing of tive r estv oihbto yCB by inhibition to sensitive are oi oei lo rsuemitnne oee,in However, CB maintenance. rats pressure blood hypertensive in role tonic er n nohlu fhpresv rats hypertensive of endothelium and heart idtp controls wild-type h nrae xrsino CB of expression patients, hypertensive increased from animal samples the hypertensive clinical either in in determination mechanism. or made no models been aware, compensatory has are levels a authors EC the of as stress as far produced hypertensive) as While, are (i.e. EC pathophysiological the of ations dilatory h adoaclrrsosst h C h simple The elicit not EC. do antagonists the receptor signi CB to that however, responses fact, cardiovascular the lo rsue hra niioso E metabolism AEA pressure of blood inhibitors normalise whereas pressure, blood n r beti CB in absent are and ohAEA Both not. do and they where ECs and exist of similarities evidence where mechanisms identify the to protective synthesise the to this of attempt for remainder therefore The will action. review of mechanisms protective n nipoeeti lcs tolerance glucose in improvement an and , subjectto theCambridgeCore termsofuse,available at ol h noanbni ytmb ehns for mechanism a be system endocannabinoid the Could h fetof effect The h fet of effects the fi atbodpesr responses pressure blood cant ( 42 n 3PF a ea motn ato their of part important an be may -3-PUFA ) n adodpesv responses cardio-depressive and ( 38 – 40 1 n- ) PLC ; n- ogcanPF nhypertension? in long-chain-PUFA 3 ( ≥ 41 n 2-AG and 1 CPF nbodpesr has pressure blood on LC-PUFA 3 gd oe of doses 3g/d) ) eetri epnil o mediating for responsible is receptor 1 ugssta Cd o lya play not do EC that suggests , β 1 ncotmc scmaal with comparable is mice knockout phospholipase , koku mice -knockout 1 ( eetratgnssincrease antagonists receptor 4 ) ugsigta ne situ- under that suggesting , ( 41 1 ) 1 eetrantagonists receptor eetr nbt the both in receptors lctcmlxvaso- complex elicit ( 4 , 13 n- ( ( 41 CPF do LC-PUFA 3 , 45 39 ) ( ) , oehrthis Together . 37 43 ) , 44 ( hw that, shows These . 4 nvivo in ) ) n n that and , ssugges- is -3-PUFA fi that nd- ( 43 ) https://www.cambridge.org/core/terms Downloaded from Proceedings of the Nutrition Society hr sagoigeiec aefrarl fteE sys- EC CB the progression. of lesion role a atherosclerotic for in base tem evidence growing a is There hypertension. in EC and LC-PUFA ugssta hr sn orlto between correlation no is NO) presumably there evidence current (and that basis, this endothelium suggests On while potent vasodilators. dependent agents, are NO-releasing EC or anti-hypertensive either CPF ntestigo yetnindfe substan- differ hypertension of tially: setting the in LC-PUFA CPF euebodpesr r numerous are pressure blood in (reviewed reduce LC-PUFA htEArlxsbodvsestruhedteilNO endothelial through show vessels preparations release blood vessel relaxes blood EPA ovine that and bovine lated nfetv nlwrn lo rsuei idessential mild in pressure patients blood hypertensive lowering in ineffective igterlaeo ircoie(NO) oxide nitric of invol- release mechanism endothelial the an ving through mediated of be setting to the in pressure blood modify hypertension. to appear only es(urgt akr fedteilfnto)i either in subjects function) endothelial normal of markers (surrogate ness W-3 teutssot ucecl proliferation cell muscle migration smooth and attenuates JWH-133 eti russc sodrhpresv ujcsand subjects hypertriglyceridaemia hypertensive with older as in individuals such only evident groups is certain this pressure), blood systolic (especially yetnin oee,tepro the However, hypertension. in LC-PUFA h ai ftefloig i h phytocannabinoid the (i) following: on the effect of anti-atherogenic ∆ an basis with the associated been has syndrome ovrey h rpsdmcaims ywhich by mechanism(s) proposed the Conversely, ihrsett h atrteei ereo ambiguity of degree a is and there experimental although latter system the between production, to NO respect renin-angiotensin with endothelial the of enhancement with interference oe oe of doses lower eihrlvsua disease vascular peripheral nohla ucini mrvdi niiul with individuals in improved diabetes II is type function endothelial CB naoit(SR144528) antagonist DA on +DHA) nossetwt hsadhv eotdn feto long- of effect no reported term have and this with inconsistent blse yc-diitainwt CB a with co-administration by abolished ua ali ihftfdApoE fed high-fat in vas- the wall to cular adhesion leucocyte suppresses and progression n non-CB and signi but small a produce ula el ssniiet CB to sensitive is cells mono- blood nuclear peripheral human in production superoxide 9 h lo rsuelwrn fet fE r thought are EC of effects lowering pressure blood The tpeetteei odt rudwehro not or whether around data no is there present At niahrslrtcefcsof effects anti-atherosclerotic ttayrcnaio eue teoceoi lesion atherosclerotic reduces -tetrahydrocannabinol ol h noanbni ytmcnrbt othe to contribute system endocannabinoid the Could 1 /CB n- https://www.cambridge.org/core ( n- 51 CPF upeetto (0 supplementation LC-PUFA 3 2 , CPF r o atclryefcieas effective particularly not are LC-PUFA 3 52 ( eetraoitWN5,1- nTNF on 55,212-2 WIN agonist receptor 46 ) ) oee,suisi ua ujcsare subjects human in studies However, . fl ( 50 hs ieteE system, EC the like Thus, . 1 wmdae iaainado reilstiff- arterial and/or dilatation ow-mediated /CB ) fl ( 59 ec Clvl ntevsuauein vasculature the in levels EC uence n nld fet nsdu excretion, sodium on effects include and ) n- ( ( 57 ) 53 CPF sasnl ramn are treatment single a as LC-PUFA 3 ) 2 , n ii h upesn feto the of effect suppressant the (iii) and 54 . ) psil aili)receptors vanilloid) (possibly . https://doi.org/10.1017/S0029665113003406 hypertensives , ( 47 fi ) ( ndings. fi 58 ridvdaswt metabolic with individuals or atdces nbodpressure blood in decrease cant ) ( 56 . IPaddress: i)teCB the (ii) ; ) noanbnisand Endocannabinoids lhuhmicrovascular although , − n- / 2 nvitro In − long-chain-PUFA? 3 fi eetrblockade receptor ie nefc htis that effect an mice, e fE and EC of les ( ( 55 170.106.34.90 37 ) ) i ohCB both via , rptet with patients or · ( 45 46 tde niso- on studies n- ) – Moreover, . LC-PUFA 3 3 2 · 2 , on 2 gdEPA 4g/d activation selective 27 Sep2021 at07:50:31 agonist α ( 48 n 3ln-hi UAi adortcin463 cardioprotection in PUFA long-chain -3 and , ( 49 1 ( n- n- n- n- 60 48 ) ) 3 3 3 3 ) . . ooyeceotrcatpoen1 rdcinin production fractions 1) and cell protein factor mononuclear chemoattractant growth monocyte (platelet-derived chemoattractant nov ouaino rcse e oatherosclerosis to stablisation key plaque and processes progression of of effects modulation prevention main involve secondary The and CHD. primary of the in plementation h eeoigpau,ti icsinwl econ on be effects will direct discussion to this related plaque, are developing the atherogenesis in ences nixdn nature. antioxidant eosrt h fetvns of effectiveness the demonstrate rs otepcuewt CB with picture the to trast CB hc cin ol ev ordc h in the reduce to serve would actions which ies xii lvtdcruaiglvl fbt AEA CB both increased of with along levels 2-AG circulating and elevated exhibit disease ncrnr plaques coronary in IS-rvnin Study GISSI-Prevenzione rpslta Ceetapoahrgncefc,signal- CB effect, pro-atherogenic through a exert ling EC that proposal -G nfc,AAatnae TNF attenuates AEA and fact, AEA may EC, which In studies endogenous ligands, the afore-mentioned 2-AG. CB from the differently synthetic of behave or all phyto- that employed mind in borne teoeei nhg-a e LDLR fed high-fat in atherogenesis elpoieainadmigration and proliferation cell htteCB the that nclue ua otcedteilcells inter-cellular endothelial aortic molecules human molecule cultured adhesion in cell adhesion vascular 1 and 1 the molecule adhesion of expression hc r rdmnnl fa anti-in an of predominantly are of which effects direct the to the between similarities identify to the is of through Since article actions (i.e. this mechanisms. indirect of metabolism) and aim plaque) lipid the in of alterations level the at (i.e. ceoi i ehnssivligsprsinof suppression involving athero- recruitment of mechanisms model murine proin via a in sclerosis development lesion ates JH13 o CB nor (JWH-133) eetrblockade receptor in u hr snwsuf conten- now of is subject there a but been long tion, has progression sclerosis atherogenic the in ather- involved either process. events on cellular effects the its in or about is ogenesis literature there of 2-AG, than dearth rather to a anti-, regard fact an With with effect. line atherogenic in pro-, more are that effects bits oee,mr eetdt aesonta neither that shown have data recent CB more However, epneadsbeun ecct in leucocyte subsequent and response the ua ct ooyi ekei el monocyte CB cells TNF to sensitive leukaemia being attenuates actions monocytic both artery adhesion, and acute coronary human human cells in 1 molecule endothelial vascu- adhesion and cell 1 molecule lar adhesion inter-cellular of pression ag-cl admsdtil DR Trial (DART trials randomised large-scale , subjectto theCambridgeCore termsofuse,available at Dietary h matof impact The 1 2 fi dnsta ainswt dacdcrnr artery coronary advanced with patients that ndings ciainrslsi teoeei sdrvdfrom derived is atherogenesis in results activation fl eetratvto ihaslcieagonist selective a with activation receptor maoygn xrsinadmacrophage and expression gene ammatory fi n- ( 1 62 holitk a endcmne olower to documented been has intake sh-oil CPF n C n ic Cin EC since and EC, and LC-PUFA 3 ) eetv naoitrmnbn i attenu- (i) rimonabant antagonist selective n i)ihbt aclrsot muscle smooth vascular inhibits (ii) and ( n- 1 64 ( CPF nevnini athero- in intervention LC-PUFA 3 ) 24 2 eetr.Hwvr tsol be should it However, receptors. ugsigta E tlatexhi- least at AEA that suggesting , ) n eetrgn eeinmodulate deletion gene receptor ae oehrwt the with together Taken . 3L-UAo lqestability, plaque on LC-PUFA -3 ( fi 66 in vdnefo several from evidence cient ( ) 70 EI Study JELIS , 2 ) n- eetr,eiec that evidence receptors, ( CPF perto appear LC-PUFA 3 63 n eraesurface decrease and ) hshsldt the to led has this , n- 1 ( − 68 eetrexpression receptor / CPF sup- LC-PUFA 3 fi , − 69 tainta fuels that ltration ) fl mice maoyand ammatory i ohdirect both via α idcdex- -induced α ( ( fl 71 61 -stimulated 1 ammatory ) ( ) 67 ohof both , n CB and ncon- In . fi ) ndings )to fi ned ( fl 65 u- ) 2 , https://www.cambridge.org/core/terms Downloaded from Proceedings of the Nutrition Society CB a ensoni oesuist euemyocardial reduce to studies hearts rat some isolated in in size infarct shown been has n ihicesdsaiiy hrceie yan by characterised stability, in increased increased consist- with changes structural ent inducing by morphology que iet ohCB both to tive ceoi lqersml eycoeytoese with seen those closely CB modulate very that agents resemble plaque sclerotic eotdfloigmoada / nuyi ohexper- been both have in animals EC injury imental circulating I/R myocardial and following tissue reported of levels Elevated death. pose arrhythmic sudden AMI through an life during to threat occur the a that while disturbances (AMI), infarction electrical damage myocardial tissue of acute cause following principal the represents injury I/R n nrae olgncneto h plaques the of content collagen increased and tesi osnot does it others o aeacuto h osbepoetv oeo the of role protective possible CB the via exerted of EC account take not ns,adicessAAidcdcrimoyecell cardiomyocyte AEA-induced death increases and onism, -Gaemr consistent more are 2-AG 464 ssmlrycon similarly is fanme fcmrhnierves(e.g. reviews comprehensive subject of the number been has a and of contention of point a remains EC eetAMI recent au tcudteeoeb rudta h anti- the in CB that pro-atherogenic their by thus argued mediated face and ence EC, be At of removal therefore EPA. by of with could effect atherogenic nor- intervention it are these dietary value that markedly and by are ApoE-/- 2-AG malised fed and high-fat AEA in vas- both and elevated of heart levels both tissue that cular shown have laboratory own our ycrilijr,a fetta srvre yCB by reversed is exacerbates that effect hydrolase an injury, amine myocardial acid doxorubicin-induced stress-dependent fatty oxidative/nitrative of gen- deletion or inhibition etic pharmacological either by metabolism iedsic rmtecasclC eetr ih be might receptors CB classical the from that distinct suggesting site a cardioprotection, 2-AG-induced mimic progression. plaque xrsini teoceoi lqe,teeaen de no are there receptor plaques, CB atherosclerotic increased in of expression evidence is there Although tem. ycrilijr i CB via injury myocardial xrsino arxmtlortiae7 9ad-12 and -9 metalloproteinase-7, matrix of expression nhg-a e mice elevated. fed similarly high-fat are in effects) recep- their the to However, mediate opposed (as that levels EC tors that show to data tive fi hs oiieefcsof effects positive These ncnrs,rprso adortcieefc of effect cardioprotective a of reports contrast, In ol h noanbni ytmcnrbt othe to contribute system endocannabinoid the Could ltration 1 https://www.cambridge.org/core bene ( n CB and 80 ) ute uprigarl o AEA-induced for role a supporting further , fi fi ( n- ilefcso ogcanPF nIHD? in long-chain-PUFA of effects cial 72 ru a hcns n eue macrophage reduced and thickness cap brous ( 75 ) CPF ordc ada Clevels EC cardiac reduce do LC-PUFA 3 eue omcl in cell foam reduced , ) 2 h ellrsuc n xc oeo the of role exact and source cellular The . 1 fl ( n CB and eetraoit do agonists receptor 9 cigaon hte rntselective not or whether around icting ) . ( 2 ycrilinjury Myocardial n,mr eety nptet with patients in recently, more and, 79 https://doi.org/10.1017/S0029665113003406 . n- ) ( n- oevr upeso fAEA of suppression Moreover, . 36 CPF lodrcl le pla- alter directly also LC-PUFA 3 1 ) CPF ol eexplained be could LC-PUFA 3 2 2 eetr;hwvr hswould this however, receptors; eetratgnss hra in whereas antagonists, receptor 1 mdae fet nteE sys- EC the in effects -mediated n nulse eut from results unpublished and . . IPaddress: ( 79 , n- 81 ) CPF nathero- on LC-PUFA 3 ( 78 lhuhteevidence the although , ) nefc hti sensi- is that effect an , fi 170.106.34.90 tainadmRNA and ltration ( 79 ) rd not do or ( 76 , on .L anrgtadL Michel L. and Wainwright L. C. , 77 ( 74 27 Sep2021 at07:50:31 ) ) 1 . .AEA ). antag- fi ( fl 73 ( ni- 78 u- ) ) , meitl ro oteosto I/R of onset the to prior immediately noeosyrlae Caeipiae sbeing as implicated are EC anti-arrhythmic released Endogenously explored. be to remains I/R myocardial of setting the in ada Osnhs ciiyi yetniehearts hypertensive in activity synthase NO cardial tes r eivdt emjrtresfrEC, for targets major be to believed in are stress, of inhibition rti iaeatvt ntebrain the in in in activity to kinase implicated known protein no are they been are heart, the also there of all Although reports have cardioprotection. NO EC-induced of generation phos- cardiolipin antioxidant mitochondrial pholipid the particular in phospho- mitochondrial lipids, of composition acid fatty altered odmntaea mrvdrsos ocrnr throm- and coronary AMI to bolysis response an of improved following an level demonstrate infarcts to smaller high well have a to for with reported evident patients Clinically, been fi to years. has opposed 20 (as events) over AMI of cardiac setting preventing the in agents oprotective euto frpruinidcdoiaiesrs and 72 stress protein shock oxidative heat of reperfusion-induced induction of reduction ieefc nps-nacinvnrclrrmdlighas demonstrated remodelling been ventricular also post-infarction on effect tive nels rlne itr intervention dietary prolonged sa as a oicamcpreconditioning ischaemic simi- to cardioprotection induce lar to described been also have hte rnot or whether pro-survival kinase protein C pathways mitogen-activated kinase protein p38 myocardial and the of activation However, receptors remote lyarl nteeefcsrmist eepoe.In explored. be to remains production, effects NO these of in terms role a play fpooe ehnssicuigatnaino platelet of function range attenuation broad including a tissue mechanisms via proposed of studies of extent numerous in the size) reduce (infarct to injury with shown been intervention has LC-PUFA dietary ation) eefso-nue rhtma hog nato at action an CB through arrhythmias reperfusion-induced a edant h adortcieefcsof effects the with cardioprotective as the similarities particular, to some In drawn LC-PUFA. and be plentiful, can are cardioprotection trbtdt ciaino CB of activation to attributed eaaayi ftet-ee xeietlstudies experimental twenty-seven of meta-analysis a n- n ua T-cells human and gis / injury I/R myocardial protection of in against form implicated endogenous potent been (a also preconditioning has 2-AG involved. , subjectto theCambridgeCore termsofuse,available at holderived sh-oil CPF sse gis /-nue arrhythmias; I/R-induced against seen is LC-PUFA 3 h rpsdclua ehnssfrEC-induced for mechanisms cellular proposed The h oeta of potential The 2 ( 87 ‘ eetr.Lkws,acerbene clear a Likewise, receptors. pre-emptive ) nrae xrsino rti iaeC kinase protein of expression increased , ( ( 85 83 ( 86 ) ) ( ( 83 xeietly rlne > ek dur- weeks (>2 prolonged Experimentally, . 90 ) n pharmacological and , n- pnn fcricK cardiac of opening , ) 84 nuto fha hc rti 72 protein shock heat of induction , CPF fetn iaeptwy in pathways kinase affecting LC-PUFA 3 ) . ( n- 83 n- ’ fl , CPF in LC-PUFA 3 CPF osmto aebeen have consumption LC-PUFA 3 99 mainadoxidative/nitrosative and ammation nuinit h ooaycirculation coronary the into infusion ( 97 n- , 100 ( ) ( 89 CPF oata ietcardi- direct as act to LC-PUFA 3 78 Arrhythmias ) n hrfr hte rntEC not or whether therefore and ) ) ( Interestingly, . rgee yischaemic by triggered ) 93 ) gis ohicamaand ischaemia both against n- . CPF upesmyo- suppress LC-PUFA 3 fl ( ( 81 90 ec mitogen-activated uence fl ( ) ( + ) 90 95 2 ( ec Oproduction NO uence osbytruha through possibly , tml,efcslargely effects stimuli, 92 atvtdCa -activated ahrta CB than rather , ) ) fi ihrwe given when either , ) nohla cells endothelial , holderived sh-oil oevr posi- a Moreover, . fi ( ilefc fthe of effect cial 91 n- n- ) rfollowing or , LC-PUFA, 3 LC-PUFA 3 δ 2+ ( ( 94 88 ( chan- ) 75 ) ( 98 and and , ( 76 n- n- 82 ( 96 ) ) 1 ) 3 3 ) ; . , , https://www.cambridge.org/core/terms Downloaded from Proceedings of the Nutrition Society CPF) h nrgigosrainta E inhibits AEA IP that observation intriguing the LC-PUFA), uwr oasu urn (o hog non-CB a through I(to) transient current cardiac the potassium of suppression outward as such LC-PUFA, gis etiua ahcri n ventricular signi and tion tachycardia afford ventricular against they that fLtp Ca L-type opening reduced of (ii) conduction), ventricular slowing and e t eue eae fe-eoaiain)and after-depolarisations) delayed Ca of release reduced spontaneous reduced (iv) (to ger icmyocytes diac uainadbokd fLtp Ca L-type of these. blockade to and as duration insight some give AEA, the data electrophysiologi- Like of direct of least at the paucity effects, on a cal studies is although there this, EC, on of effects antiarrhythmic activity). triggered (reduced reticulum plasmic CB rhtmcefcshv entoogl reviewed thoroughly been have effects arrhythmic acpamcrtclm( nw cinof action known (a reticulum sarcoplasmic enn h feto E nCa on AEA of effect the cerning rpyilgclefcsta r o hrdwt the with shared not elec- are exerts that also effects AEA trophysiological However, mechanism. common a eoaiain) ii nefc nteNa the on effect an (iii) depolarisations), nucleus i lwn fteNa the as of of such effects changes slowing direct electrophysiological (i) to in due resulting largely rents, be to n- believed are and of effects antiarrhythmic the into CPF ncrimoyetasebaecur- transmembrane cardiomyocyte on LC-PUFA 3 3 ntrso h ellrmcaim neligthe underlying mechanisms cellular the of terms In idcdCa -induced 2 ( eetrmdae aha n umnainof augmentation and pathway receptor-mediated 101 https://www.cambridge.org/core ) ( h ehnssrsosbefrteeanti- these for responsible mechanisms The . 104 n- ) CPF,AAsprse cinpotential action suppresses AEA LC-PUFA, 3 ugssta hsmyb ot usigas pursuing worth be may this that suggests ( 2+ 103 2+ ) teoeei n ycrilicama E,aadmd;2A,2aahdnlglycerol; 2-arachidonyl 2-AG, anandamide; CB ethanolamine; AEA, eicosapentaenoyl EPEA, ischaemia. ethanolamide; docosahexaenoyl myocardial DHEA, and atherogenesis 3. Fig. eetrtp 2. type receptor u lhuhteeaen aacon- data no are there although but , hnes(hsrdcn al after- early reducing (thus channels . ees rmtecardiomyocyte the from release https://doi.org/10.1017/S0029665113003406 + clu nie rpsdmcaimof mechanism Proposed online) (colour fi urn rdcn excitability (reducing current atpoeto particularly protection cant . IPaddress: noanbnisand Endocannabinoids n- CPF revealed LC-PUFA 3 2+ 170.106.34.90 2+ 2+ ees rmthe from release hnesi car- in channels rmtesarco- the from + /Ca 2+ , on exchan- 27 Sep2021 at07:50:31 fi brilla- n 3ln-hi UAi adortcin465 cardioprotection in PUFA long-chain -3 ( 102 n- n- 1 3 3 ) / n- eesaecnitnl ent eu-euae nthese EC in while up-regulated be that to However, is conditions, seen pathological mechanisms. consistently hypothesis underlying are this levels the to in counterintuitive part a by system play EC effects the of antiarrhythmic modulation that and tissue-sparing both of the both for of effects vasculo-protective n- the underlying mechanisms o in not nevtn h heart the nerves AEA innervating sympathetic Moreover, from release effect. noradrenaline antiarrhythmic suppresses an to contribute nahrgnss hsrie h nrgigpossibility intriguing the the exists. be raises may EC connection this in that similar atherogenesis, a the in and states, in that CVD that many consider role in cardinal play to the Considering IHD atherosclerosis in both and of effects the regarding similarities i;ti si otatwith contrast in is ischae- this early mia; during arrhythmias catecholamine-related both suf are there hypertension, of setting the in evident exist between is link it a while that discussion, afore-mentioned the From h T-estv oasu urn (AP through I(KATP) current aCB potassium ATP-sensitive the V elne otoeo h noanbni system? endocannabinoid the of those to linked be CVD LC-PUFA 3 CPF.Smlry omnmcaim exist mechanisms common Similarly, LC-PUFA. 3 a h bene the Can , subjectto theCambridgeCore termsofuse,available at 2 n- fl dpnetmechanism -dependent ec ada yptei tone sympathetic cardiac uence CPF n Co in on EC and LC-PUFA 3 n- CPF n C gi asn h notion the raising again EC, and LC-PUFA 3 – noanbni neato in interaction endocannabinoid fi ilefcsof effects cial n- ( 106 ‘ CPF n Ci nieyto unlikely is EC and LC-PUFA 3 isn link missing ) hc ol oetal reduce potentially would which , n- CPF edt suppress to tend LC-PUFA 3 2 cannabinoid , ( 105 n- n 3ln-hi-UAin long-chain-PUFA -3 CPF,wihdo which LC-PUFA, 3 ) oho hc would which of both , ’ fl nudrtnigthe understanding in maoyprocesses ammatory n- ( CPF may LC-PUFA 3 107 fl maoycells ammatory ) . fl ec of uence fi cient https://www.cambridge.org/core/terms Downloaded from Proceedings of the Nutrition Society 466 ae,wihte c as act then which gates, None. rtos Caecnetdto converted are EC trations, tdnsi F/704250.TeBiihHeart article. this of British writing the in role The no had PhD Foundation (FS/07/054/23590). Foundation Heart British a Studentship by supported was M. L. None. can hypothesis refuted. this or proven before but this, be warranted for are explanation attractive studies an further is bene EC, the the to of linked effects receptors act CB that conjugates the on of preferentially generation the in resulting possibly ua n os leucocytes mouse and human taoaiebt idt CB to eicosapentaenoyl bind both and ethanolamine ethanolamide bene docosahexaenoyl the of some for LC-PUFA oycells tory CPF,i spoal oepoal htthese the that in shift probably a of more consequence probably a are is changes it LC-PUFA, eany taoaiehsbe hw oexert to shown been RAW264 has anti-in ethanolamide hexaenoyl eoeloe htteE r nw oata sites at act to known are CB classical EC the the than other that overlooked be ht ntepeec fhigh of presence the in that, hsatrteblnebtenatvto fCB of activation between balance the alter thus eainhp xs ewe h w nteeefcs The all) effects. means these no in two that by fact the (but suf between some are exist the that relationships there in suggest AMI, least to and at similarities atherosclerosis speaking, of set- Mechanistically setting the CVD. in of effects protective ting demonstrate each 2-AG that and doubt no is There tested. been yet as not although has this receptors, aware CB are we from as distinct far sites at actions the E,dcshxeolehnlmd per ohv a have to af greater appears ethanolamide docosahexaenoyl AEA, eetr nfvu fCB of favour in receptors eicosapentaenoyl compensatory and ethanolamine in by ethanolamide resulting docosahexaenoyl system the lipids, in membrane EC increases of the ance overall of an as activity interpreted be of may this reduction While levels. EC n- https://www.cambridge.org/core LC-PUFA 3 fl maoyefcsi os eioeland peritoneal mouse in effects ammatory ( n- fi · 108 macrophages 7 iyfrCB for nity – CPF in LC-PUFA 3 ) Ccnuae a npr eresponsible be part in may conjugates EC htti ieymasa ellrlvlis level cellular a at means likely this what ; ( 33 ) ned ti luil htthese that plausible is it Indeed, . n- Con . CPF-eie clconjugates acyl LC-PUFA-derived 3 Acknowledgements – https://doi.org/10.1017/S0029665113003406 iaca support Financial Ccnuae a iial exert similarly may conjugates EC fi 2 ilefcsof effects cial Conclusions fl hnfrCB for than n- cso interest of icts 2 ( CPF n h CAEA EC the and LC-PUFA 3 110 fl ‘ . IPaddress: ( 1 surrogate i.3 Fig. ec noeosE levels, EC endogenous uence /CB ) oevr ncnrs to contrast in Moreover, . n- 2 LC-PUFA 3 n- 1 .Hwvr tms not must it However, ). eetr n therefore and receptors ( CPF concen- LC-PUFA 3 108 n CB and 1 170.106.34.90 nhmnin human in , n ’ , 3L-UA since LC-PUFA, -3 109 CB ) 2 2 n docosa- and gnssand agonists , on .L anrgtadL Michel L. and Wainwright L. C. eetr in receptors n – -3/ Cconju- EC 27 Sep2021 at07:50:31 1 fl n amma- 6bal- -6 v. fi fi cient CB cial n- n- 3 3 2 h nomto rmteltrtr o hsreview. this for literature the the gathering drafted to W. from C. contribution information equal an the made authors Both , subjectto theCambridgeCore termsofuse,available at 6 od ,KnoH aaeS Nakane H, Kondo S, Kondo 16. 5 u X sbiK kmt Y Okamoto K, Tsuboi YX, Sun 15. 3 ie R(09 noanbnisadteheart. the H Cadas and A, Fontana V, Marzo Endocannabinoids Di 14. (2009) CR Hiley 13. 2 ete G(07 P5:anwmme ftecanna- the of member new a GPR55: (2007) RG Pertwee 12. DA Andersson J, Petersson PM, Zygmunt 11. 0 aehM uhpdyyP akiS Batkai P, Mukhopadhyay M, Rajesh 10. .DfrN a ,Sutn R Souktani J, Wan N, Defer 9. .NmD,LeM,KmJE Kim MH, Lee DH, Nam 8. .Dl J osR,WyeJ Whyte RA, Ross CJ, Daly 7. J Narayanan AR, Lange D, Gebremedhin 6. .Pce ,Bta uo 20)Cardiovascular (2005) G Kunos & S Batkai P, Pacher 5. D Osei-Hyiaman P, Pacher S, Batkai 4. .MnoS hmsK b-ha 19)Molecular (1993) M Abu-Shaar & KL Thomas S, Munro 3. .MtuaL,Lli J rwsenMJ Brownstein SJ, Lolait LA, Matsuda 2. .Mneuc iMroV(02 ttehato the of heart the At (2012) V Marzo Di & F Montecucco 1. -rcioollcrl nedgnu cannabinoid endogenous identi agonist: receptor an 2-arachidonoylglycerol, ilatoso hshlps 2adlysophospholipase and A2 phospholipase D. of sequen- actions by tial N-palmitoylethanolamine and anandamide of ncnrlneurons. anandamide central cannabinoid in endogenous of inactivation and Pharmacol Cardiovasc J iodrcpo clan? receptor binoid vaso- the anandamide. mediate of nerves action sensory dilator on receptors Vanilloid Physiol Circ adhesion. Heart monocyte-endothelial Physiol J and Am monocytes, of migra- tion transendothelial activation, cell endothelial TNF-alpha-induced human attenuates stimulation CB2-receptor ls uvvladpoet gis ischemia/ against protects and 2120 cardiomyopathy. survival reperfusion-induced blast odrcpo ye2pooe ada yct and myocyte cardiac promotes 2 type receptor mice. noid db/db lipid in resistance, nephropathy insulin diabetic Endocrinology improves and 1 metabolism, receptor nabinoid oetr and adre- of distribution noceptors heterogeneous reveals binding ligand arteries. current. Ca2+ L-type enhances Physiol which vasoconstric- cyto- J the express 20-HETE produce cells and tor enzyme muscle 4A2 smooth P450 chrome arterial cerebral Cat 168 cannabinoids. of pharmacology euaecrivsua ucini hypertension. in function receptors cannabinoid-1 cardiovascular Circulation at regulate acting Endocannabinoids hrceiaino eihrlrcpo o cannabinoids. for Nature receptor peripheral a of characterization tutr facnaiodrcpo n functional and receptor cDNA. cannabinoid cloned the a of expression of Structure atr h noanbni ytmi cardiovascular dysfunction. in and system endocannabinoid function the matter: 331 ice J Biochem 599 , – – 340. 2130. 365 – rJPharmacol J Br 625. 507 ,61 110 t3 771 3, Pt , 380 – 153 1996 , fi 65. a eso ftereview. the of version nal ‘ cannabinoid-like t3 749 3, Pt , 1387 , Nature Authorship References – rJPharmacol J Br 2002. fi – aina n ftemjrspecies major the of one as cation – 53 781. 159 1396. 372 267 , – tal et 787 , rnsPamclSci Pharmacol Trends 756. 686 , Nature tal et tal et – tal et 21)Bokd fcan- of Blockade (2012) . Nature 276. ad x Pharmacol Exp Handb – 293 tal et ’ 796. 20)Tecannabi- The (2009) . – 21)Fluorescent (2010) . 691. 20)Biosynthesis (2004) . eetr nsmall in receptors H2210 , 400 152 19)Formation (1994) . 346 AE J FASEB 452 , 984 , tal et tal et tal et 561 , tal et tal et tal et – H2218. – – 457. 986. (1998) . (2004) . (2007) . – (1990) . (1998) . (1999) . 564. fi bro- 23 33 , , https://www.cambridge.org/core/terms Downloaded from Proceedings of the Nutrition Society 3 odJ,Wlim S adrnta L Pandarinathan JS, Williams JT, Wood 33. 2 egrA rze ,BsgoT Bisogno G, Crozier A, Berger 32. emer- fat: treat to Fat (2013) BA Watkins & Y Li J, Kim 31. 0 ejrn ,BlesM&WtapR(03 N-acyl (2013) R Witkamp & M Balvers J, Meijerink 30. 9 tne C hialhR akwk R(2012) ER Dabkowski & RJ Khairallah WC, Stanley 29. 8 eCtrn apliA(07 mg- at acids, fatty Omega-3 (2007) A Zampolli & R Caterina De 28. 7 ugU,Treo ,TgeAP Tighe C, Torrejon UJ, Jung 27. the underlying Mechanisms (2010) DS Kelley & Y Adkins 26. 5 uril ,Ptk ,Vnet G Vincenti Z, Pataky A, Quercioli 25. 4 uauaK uiaaS oaiT Nozaki S, Sugiyama K, Sugamura 24. 0 uaaah ,TkysiI ohnr D Yoshinari I, Takeyoshi M, Kurabayashi 20. 3 aehM akiS ehi M Kechrid S, Batkai M, Rajesh 23. J Bauersachs K, Hu JA, Wagner 21. WR Schabitz PC, Schmid C, Berger receptors 19. Cannabinoid (2002) RA Ross & RG Pertwee 18. 2 esF ersFradzA oinR Sodian A, Beiras-Fernandez F, Weis 22. and biosynthesis Endocannabinoid (2010) GG Muccioli 17. nbanadplasma. alters and brain metabolites supplementation in endocannabinoid-system physiological acid select docosahexaenoic Dietary eanaelast nrae ri eeso h corre- A piglets. S the U in of Sci levels Acad docosa- N-acylethanolamines brain and increased sponding arachidonate to dietary leads of hexaenoate inclusion diet: and endocannabi- 104-105 obesity. PUFA, and dietary noids, between relationship ging illeads. tial mnso ooaeani cdadohrn3polyunsa- n-3 other acids fatty and tured acid docosahexaenoic of amines urMtbCare acids. of Metab fatty impact Nutr polyunsaturated function: mitochondrial n-3 and dietary lipids on Update teoeei,adedteilactivation. Med endothelial and atherogenesis, cd n adoaclrdsae ehnssunderlying mechanisms bene disease: cardiovascular and acids fatty polyunsaturated acids. omega-3 of effects cardioprotective 1369 r icltr yfnto nobesity. in dysfunction coron- circulatory with ary associated are levels plasma endocannabinoid 28 eetrbokd nmacrophages. on artery blockade coronary receptor antiin in and system disease endocannabinoid Activated Diabetes eetrpooe ada yfnto,oiaiestress, oxidative dysfunction, in cardiac promotes receptor 1 liver. rat the of ischemia-reperfusion injury in increases 2-arachidonoylglycerol ischemia? cerebral Cell 1159 acute stroke. in after signalling N-acylethanolamines of accumulation ligands. Acids their and eetr2adatvtdedcnaiodsse in system endocannabinoid failure. 1187 heart activated severe with cannabinoid and patients of 2 pattern receptor expression altered Substantially experimental after hypotension infarction. myocardial mediate cannabinoids nciain rmsml ocomplex. to simple Today from inactivation, idpnetmechanisms. -independent o t eeaintruhCA through generation evidence its and tissues, rat for various in monoacylglycerols of https://www.cambridge.org/core fl – main and ammation, 36. fi – – – 8 ileffects. cial 1378. 1167. 1193. 66 urBiochem Nutr J up.1 S11 1, Suppl. , 15 ,32 101 , 61 474 , rJPharmacol J Br – 716 , 41. – – 121. 483. – – 98 . 727. mJCi Nutr Clin J Am https://doi.org/10.1017/S0029665113003406 15 from fl 6402 , fi maoyefcso anbni 1 cannabinoid of effects ammatory rsalnisLuo setFatty Essent Leukot Prostaglandins 122 , rsalnisOhrLpdMediat Lipid Other Prostaglandins – rssi ibtccardiomyopathy. diabetic in brosis ii Res Lipid J S14. netSurg Invest J 21 mCl Cardiol Coll Am J fi 781 , – – h noanbnist poten- to endocannabinoids shy . IPaddress: 6406. 126. 169 ESLett FEBS noanbnisand Endocannabinoids – 772 , 792. tal et tal et tal et 51 87 o elCardiol Cell Mol J tal et – 170.106.34.90 tal et 1416 , 21)Cannabinoid (2012) . 20)Anandamide (2001) . 18 783. 2003S , tal et 20)Endogenous (2001) . 2+ 429 ,25 20)n3fatty n-3 (2008) . Neurochem J dpnetand -dependent 21)Elevated (2011) . Circulation u er J Heart Eur 20)Massive (2004) . urOi Clin Opin Curr 152 , 38 – – tal et 1423. 31. rgDiscov Drug tal et Cardiovasc J – tal et 2048 , tal et 2009S. , on rcNatl Proc – 156. (2009) . 27 Sep2021 at07:50:31 (2010) . (2010) . (2005) . – n 2054. 3ln-hi UAi adortcin467 cardioprotection in PUFA long-chain -3 119 88 32 48 , , , , 0 ieoA,EtkS&Brh 20)Oea3polyun- Omega-3 (2009) C Borghi & S Ertek AF, Cicero 50. (2007) S Mukhopadhyay & AC Howlett L, McCollum 49. 7 us ,Oiir ,GrliD Girelli O, Olivieri C, Russo 47. 8 aiosaB wlkG&GtetM(2001) M Gothert & G Kwolek B, Malinowska 48. 6 ieoA,Drs ,D rgr V Gregori acids Di fatty G, Derosa Omega-3 AF, (2012) Cicero P 46. Mata & R Alonso J, Cabo 45. 4 anrJ,VraK li EF Ellis K, Varga JA, Wagner 44. 3 ag ,Lk ,Mri BR Martin K, Lake K, Varga 43. E Schlicker & M Baranowska-Kuczko B, Malinowska 42. K Varga JA, Wagner Z, Jarai 41. 9 aeK,Mri R uo G Kunos BR, Martin KD, Lake 39. D Huangfu KD, Lake K, Varga 38. 0 ahrP akiS siHimnD Osei-Hyiaman S, Batkai P, Pacher 40. 7 oses ,JloaZ,Kd O Kuda ZM, Jilkova M, Rossmeisl 37. T Bisogno G, Carta F, Piscitelli 36. 5 aet ,Ginr ,CraG Carta M, Griinari B, Batetta 35. 4 aaaeS oh aaaiT(03 n-3 (2003) T Hamazaki & M Doshi S, Watanabe 34. , subjectto theCambridgeCore termsofuse,available at auae at cd:terptnilrl nbodpressure blood in role potential their acids: fatty saturated endo- aortic cells. rabbit thelial in production oxide receptor nitric independent cannabinoid CB1/CB2 Anandamide-mediated lo rsuemntrn aaeesi ainswith ambulatory patients and in hypertension. parameters essential supplements mild monitoring pressure acid blood fatty unsaturated er aeadbodpesr naashtzdrats. anaesthetized in pressure Pharmacol blood Arch Schmiedebergs and Naunyn rate in changes heart receptor-mediated CB1 cannabinoid vanilloid and both VR1- induce methanandamide and Anandamide 1823 eaoi ydoe ersetv study. retrospective with a Hypertens patients syndrome: without or hypertriglyceridemic with metabolic and pressure in blood normal-high blood untreated and levels supplementation pressure acids fatty polyunsaturated pressure. blood and eihrlC1cnaiodrcposi haemorrhagic in receptors shock. cannabinoid CB1 peripheral ns mlctsteC1cnaiodrcpo nthe in anandamide. receptor of cannabinoid 278 CB1 action mechanism? the hypotensive the implicates onist understand cannabi- we to responses Pharmacol do pressure blood noids: Triphasic (2012) A receptors. S CB2 U or endothelial Sci CB1 an from distinct through site vasodilation mesenteric induced n osiu omtnieadhpresv rats. hypertensive and anesthetized normotensive in Hypertension conscious anandamide of and effects Cardiovascular anesthetized in anandamide of action rats. hypotensive the of lase. barore pro Hemodynamic are poss- diet: phospholipids high-fat endocannabinoids. a as of fed role mice PUFA ible in n-3 triglycerides to of superior effects Metabolic fmtblclyrlvn ise rmhg-a-e mice. high-fat-fed from Metab tissues Nutr relevant endocannabinoidome metabolically the on of supplementation oil krill ary noeeZce rats. Zucker obese in cd ordc coi a n in and fat fatty ectopic (n-3) reduce of to ability acids the mediate may Endocannabinoids Acids mice. 2-arachidonoyl- in brain level reduces glycerol enrichment PUFA n-3 and oynauae at cd(UA de (PUFA) acid fatty Polyunsaturated 279 , – mJPyilHatCr Physiol Circ Heart Physiol J Am Hypertension 1826. 69 fl Nature xestvto ielcigatai md hydro- amide lackingfattyacid mice exsensitivityof – ,51 283. 32 96 165 – hrao x Ther Exp Pharmacol J 8 137 , 14136 , 59. 29 51-7075-8-51. , 390 2073 , 1204 , – 518 , fi 28 144. e epnieest nnaie and anandamide, to responsiveness le, rJNutr J Br – – 682 , Nutr J 14141. 2088. – rsalnisLuo setFatty Essent Leukot Prostaglandins – 1210. 521. – 686. Hypertension J 139 tal et tal et 107 lSONE PloS tal et tal et tal et 1495 , tal et 19)Oea3poly- Omega-3 (1995) . up.2 S195 2, Suppl. , fl 19)Cannabinoid- (1999) . 19)Nvlantag- Novel (1995) . 21)Efc fdiet- of Effect (2011) . 19)Atvto of Activation (1997) . 321 maoymediators ammatory tal et . 19)Mechanism (1996) . 289 – u Pharmacol J Eur 930 , 1501. 21)Oea3 Omega (2010) . 364 fi H533 , rcNt Acad Natl Proc inyelevates ciency tal et tal et 7 tal et tal et e38834. , 562 , – 13 937. ,12Pt2, lnExp Clin – (2009) . (1997) . (2012) . (2005) . – H541. 569. – rJ Br 200. – https://www.cambridge.org/core/terms Downloaded from Proceedings of the Nutrition Society 468 6 IS-rvnin netgtr 19)Deaysup- Dietary (1999) Investigators GISSI-Prevenzione 66. 4 aehM uhpdyyP akiS Batkai P, Mukhopadhyay M, Rajesh 64. 5 urM,Fhl M ibr JF Gilbert AM, Fehily ML, Burr 65. 3 aehM uhpdyyP ak G Hasko P, Mukhopadhyay M, Rajesh 63. 0 emi ,BihtE deirC Advenier E, Boichot N, Germain 60. 2 o-lie ,Puel ,Vsni V Visentin R, Paumelle F, Dol-Gleizes 62. A Rodriguez Ortiz K, Zeschky F, Willecke 61. 5 oda J oiT,BreV Burke TA, Mori RJ, Woodman 55. 6 akyI odI he F Thies I, Ford I, Mackay 56. 7 tra ,Nnra ,GtigC Gotting S, Nandrean A, Stirban 57. 9 aehM uhpdyyP ak G Hasko P, Mukhopadhyay M, Rajesh 59. C Arnaud NR, Veillard S, Steffens 58. 4 klsRyA,Ki-tetnP,Hri WS Harris PM, Kris-Etherton AC, Skulas-Ray 54. 3 adr A alW,Mno Z Maniou WL, Hall TA, Sanders 53. 2 ig U ahre ,CoduyS Choudhury K, Kathirvel TU, Singh 52. 1 mr ,KbysiS iuaiY Mizukami S, Kobayashi M, Omura 51. lmnainwt - oynauae at cd and acids fatty polyunsaturated n-3 with plementation irto fmncts n monocyte-endothelial transendothelial and activation, monocytes, adhesion. cell of migration endothelial TNF-alpha-induced human attenuates stimulation CB2-receptor ada enacin itadrifrto ra (DART). trial reinfarction and Lancet diet reinfarction: cardial proliferation. and Commun Res migration Biophys vascular muscle decreases inhibition smooth receptor CB1 Cannabinoid hne nfat, in changes H2218. ns,ihbt teoceoi nLLreceptor-de LDL in mice. atherosclerosis inhibits antag- receptor onist, CB1 cannabinoid selective a Rimonabant, anbni eetr2sgaigde o modulate not does signaling mice. in 2 atherogenesis receptor Cannabinoid yetnietp ibtcpatients. diabetic 2 166 type platelet, hypertensive on acid puri of hypertriglyceridemia. moderate Nutr Clin with J Am persons healthy tri- in on acids fatty glycerides, omega-3 of effects Dose-response (2011) nohla ucini ainswt eihrlarterial and peripheral platelet with of patients disease. in markers function on endothelial supplementation acid fatty xd no n N-lh rdcinb ua mono- human cells. by nuclear production TNF-alpha super- and on anion 55,212-2, oxide WIN ligand, receptor cannabinoid the TNF-alpha- proliferation cell migration. attenuate muscle and smooth vascular agonists human induced receptor cannabinoid athero- of mice. progression in reduces sclerosis therapy cannabinoid oral mellitus. diabetes 2 91 type with subjects n inadatra tfns:arnoie otoldtrial. controlled Nutr randomized Clin a J stiffness: Am arterial and tion o oe flong-chain of doses low n idpnetrlxto fsepploayartery. pulmonary Pharmacol sheep J of Eur relaxation endothelium-dependent -independent and acid-induced Eicosapentaenoic ytaeadedteimdpnetvasorelaxation. oxide endothelium-dependent Lett nitric FEBS and endothelial of synthase translocation and activation Ca(2+)-independent induces (EPA) acid Eicosapentaenoic 330 rvninadmanagement. and prevention https://www.cambridge.org/core − 808 , at cd nmco n irvsua ucinin function microvascular and macro- on acids fatty 3 ,85 – 337. reislrTrm acBiol Vasc Thromb Arterioscler – – fi 2 Atherosclerosis 93. 813. decspnani cdaddocosahexaenoic and acid eicosapentaenoic ed 757 , mJPyilHatCr Physiol Circ Heart Physiol J Am 487 – n Immunopharmacol Int fl 761. 361 , main n nohla ucinin function endothelial and ammation, . fi rJPharmacol J Br https://doi.org/10.1017/S0029665113003406 93 94 h and sh, Nature 636 fi 243 , 973 , rnltcadvsua ucinin function vascular and brinolytic – 366. 108 , 377 lSONE PloS 221 – – n . IPaddress: fi 252. 980. 434 − 1248 , – r nae ndahadmyo- and death on intakes bre tal et UA nedteilfunc- endothelial on PUFAs 3 514 , 113. 782 , 21)Efc fOmega-3 of Effect (2012) . urVs Pharmacol Vasc Curr – 153 – 1252. 520. – 170.106.34.90 6 tal et 786. tal et tal et e19405. , tal et 347 , tal et 2 tal et 29 537 , 18)Efcsof Effects (1989) . ,12 20)Lwdose Low (2005) . 21)Efcsof Effects (2010) . 21)Efc of Effect (2011) . tal et 20)Efc of Effect (2002) . mJCi Nutr Clin J Am – 20)Effects (2003) . 357. – Atherosclerosis – 543. tal et tal et , on .L anrgtadL Michel L. and Wainwright L. C. tal et tal et tal et 18. 293 20)CB2 (2008) . tal et 27 Sep2021 at07:50:31 H2210 , Biochem (2010) . (2001) . (2009) . (2007) . (2008) . (2011) . fi tal et cient 7 – . , , subjectto theCambridgeCore termsofuse,available at 1 anrJ,AesrM avyWieJ Harvey-White M, Abesser JA, Wagner 81. 0 uhpdyyP ovt ,Rjs M Rajesh B, Horvath P, Mukhopadhyay 80. 9 eiirP ocadJ,LgexC Lagneux JF, Bouchard P, Lepicier 79. J Bu LS, Jiang PF, Wang 75. 8 nedw J ie R&Fr R(2005) WR Ford & CR Hiley NJ, endo- the Underdown Targeting 78. (2012) S Steffens & RF Tuma 77. 4 asmt ,St ,Fkd D Fukuda M, Sata M, Matsumoto 74. 6 ahrP&HsoG(08 noanbnisadcan- and Endocannabinoids (2008) G Hasko & P Pacher 76. FL Napper R, Ding AL, Cawood 73. 2 he ,GryJ,Yqo P Yaqoob JM, Garry F, TS Thies 72. Lee CJ, Chen TM, Wang 71. I Larass F, Hessel KH, Baumann 70. 9 eiaaA ubJ,UsiaH Ueshima JD, Curb A, Sekikawa 69. 8 o cak ,AgrrP ohyW Kothny P, Angerer C, Schacky von 68. 7 ooaaM rgs ,MtuaiM Matsuzaki H, Origasa M, Yokoyama 67. osmdae eae adortcinidcdb nitric by induced cardioprotection delayed recep- mediates cannabinoid tors CB1 on acting 2-Arachidonylglycerol at cdaiehdoaei e euao of regulator key a is Med Biol injury. hydrolase Radic tissue myocardial amide endocannabinoid-induced acid Fatty noanbnispoettertioae er against heart isolated rat ischaemia. the protect Endocannabinoids Atherosclerosis etdt shei-eefso yanvlcannabinoid novel a by mechanism. ischaemia-reperfusion sub- hearts to isolated rat jected in size infarct reduces Anandamide cerebral and myocardial injury. 13 limit reperfusion and to ischemic system cannabinod injury. ischemia- heart and infarct ApoE-de reperfusion against protects activation receptor in lesions stabilizes and atherosclerotic reduces acid eicosapentaenoic administered aiodrcposi shei-eefso nuyand injury ischaemia-reperfusion preconditioning. in receptors nabinoid 301 in plaque associ- stability. is advanced decreased EPA into with plaque incorporated ated higher is and esters plaques concentrated ethyl atherosclerotic highly acid fatty from n-3 (EPA) acid Eicosapentaenoic ceoi lqe:arnoie otoldtrial. controlled randomised 361 a plaques: sclerotic TNF-alpha-treated n in cells. endothelial activation 187 aortic expression NF-kappaB human VCAM-1 attenuates and acid gene Docosahexaenoic cytokine and factor Biol study. A monocytes. volunteer growth stimulated randomized and unsaturated unstimulated and omega-9 in expression acids and omega-6, fatty omega-3, Dietary aaee aaeeAeia,adwiemn cross- in a atherosclerosis men: white and study. sectional and acids Japanese-American, fatty Japanese, n-3 Marine-derived feto itr mg- at cd ncrnr athero- coronary placebo-controlled trial. on double-blind, randomized, acids A fatty sclerosis. omega-3 dietary of effect analysis. coronary endpoint major ran- blinded 369 a on open-label, (JELIS): patients domised acid hypercholesterolaemic in eicosapentaenoic events of Effects iai fe ycrilifrto:rslso the of Studio lo 447 results nell per infarction: Sopravvivenza Italiano della Gruppo myocardial trial. after GISSI-Prevenzione E vitamin − ,46 oynauae at cd ihsaiiyo athero- of stability with acids fatty polyunsaturated 3 – 477 , – 1090 , – 307. 194. 455. 19 n nenMed Intern Ann – ,59 58. – Atherosclerosis 485. – 1098. – rJPharmacol J Br 66. rJPharmacol J Br 197 mCleeCardiol College Am J 50 rJPharmacol J Br 179 , 524 , 130 – – ’ 212 195. 533. nat miocardico. Infarto 554 , adoacPharmacol Cardiovasc J 139 252 , tal et 146 tal et – reislrTrm Vasc Thromb Arterioscler fl 805 , 562. mainadincreased and ammation 809 , – 21)Cannabinoid-2 (2012) . 153 urPamBiotechnol Pharm Curr 259. 20)Ascainof Association (2003) . urBiochem Nutr J – 252 , 815. – tal et 52 816. tal et 417 , tal et – 20)Orally (2008) . fi tal et tal et tal et 262. tal et in mice. cient tal et tal et tal et 19)The (1999) . Lancet – 424. (2011) . (1999) . (2010) . (2008) . (2003) . (2007) . (2006) . (2011) . Lancet Lancet Free 354 59 22 , , , https://www.cambridge.org/core/terms Downloaded from Proceedings of the Nutrition Society 6 u ,WnM ogD Song M, Wan H, Xue 96. 5 a S rlyR,DMrJ Jr JC DeMar RN, Ertley JS, Rao 95. 4 eiirP ieuPiirA anu C Lagneux A, Bibeau-Poirier P, Lepicier 94. enhances JO Beitnes RK, Anandamide Berge LE, (2013) Fosshaug 93. B Li & M Shi Q, Li 92. 1 cunesJ elnT,Saks A Sharkasi TG, Neilan J, McGuinness 91. 0 bueu G wnA cennP (2008) PL McLennan & AJ Owen GG, Abdukeyum 90. 4 otccoF ege ,BanrruhrV Braunersreuther S, Lenglet F, Montecucco 84. 9 O 89. M Ghasemi S, Tavakoli AR, Hajrasouliha 83. 2 ocadJ,Lpce aotgeD(2003) D Lamontagne & P Lepicier JF, Bouchard 82. 6 h Q ivr E u YP Sun RE, Sievers BQ, Zhu 86. P Urdal M, Abdelnoor K, Landmark 85. 8 lvcoaM ekrJ ekv J Jezkova J, Neckar M, Hlavackova 88. H Asanuma K, Node H, Ogita 87. cdaddcshxeocai ouaemitogen- endothelium. modulate in activity acid Pharmacol kinase docosahexaenoic protein activated and acid in cascades acid cortex. docosahexaenoic frontal rat and arachidonic the n inln ahasivle ntecardioprotective the in cannabinoids. involved of effects pathways Signaling infu- acid fatty quanti omega-3 sion: an using protection Myocardial xrsino etsokpoen7 opoetagainst protect heart. to rat 72 63 in protein injury shock ischemia-reperfusion heat of expression Surg Cardiovasc teutslf etiua iaainatrmyocardial after dilatation rats. in ventricular infarction left attenuates preconditioning. ischemic by enhanced Nutr not J heart in infarction and rat arrhythmias reperfusion and ischemia bit itr ( Dietary transition. meability xd nrtioae hearts. isolated rat in oxide hshlpdcmoiinaddlyCa delay mitochondrial and cardiac alter composition acids phospholipid fatty omega-3 Dietary the in receptors CB2 heart. cannabinoid rat ischemic via remote to preconditioning contribute cannabinoids Endogenous eto foddb shmcpeodtoigi h iso- the in heart. preconditioning rat ischemic lated by pro- afforded endothelial the tection in endocannabinoids of Contribution 650 namuemdlo ischemia/reperfusion. of model Cardiol mouse a cardioprotective is in activation receptor cannabinoid CB(2) oynauae at cd le ycrilprotein induced cardioprotection myocardial hypoxia. affect chronic and alter by expression C acids kinase fatty polyunsaturated ischemia hearts. 41 by rabbit in induced reperfusion injury and myocardial reduces acid noic dietary function? by platelet altered size infarct myocardial of activities. dehydrogenase lactate Cardiology and kinase creatine peak fi − hol per ordc nac iea siae from estimated as size infarct reduce to appears oils sh ’ https://www.cambridge.org/core ,47 964 , haK,Karla J prgaGC Sparagna RJ, Khairallah KM, Shea UAdpiainatr xrsino nye of enzymes of expression alters deprivation PUFA 3 – 655. – 53. – 138 46 969. n u Pharmacol J Eur − 612 , 1902 , 44 89 )ln-hi oynauae at cd inhi- acids fatty polyunsaturated long-chain 3) fi ainadmcaimo action. of mechanism and cation 434 , ,94 – ieSci Life 620. 132 – . – iisHat Dis Health Lipids https://doi.org/10.1017/S0029665113003406 1909. o Psychiatry Mol – 102. 439. ,72 x ilMed Biol Exp o elCardiol Cell Mol J – 72 hrao Sci Pharmacol J mHatJ Heart Am 79. . IPaddress: 1859 , tal et noanbnisand Endocannabinoids 579 adoacPharmacol Cardiovasc J tal et tal et 246 , 20)Eicosapentaenoic (2006) . – adoacPharmacol Cardiovasc J 19)I h reduction the Is (1994) . 1870. 12 20)Eicosapentae- (2003) . 170.106.34.90 232 10 – tal et 127 151 , tal et tal et 252. fi tal et 245-511X-10-245. , holtersl of result the oil sh 823 , t1 744 1, Pt 4 , 47 20)Dietary (2007) . 21)Kiloil Krill (2011) . 20)Dietary (2007) . 102 2+ – 19)Ueof Use (1998) . 819 , 157. hso Sci Physiol J idcdper- -induced tal et – tal et tal et tal et 155 , 832. tal et , on o Cell Mol J – Thorac J 27 Sep2021 at07:50:31 (2006) . 827. (2006) . (2008) . (2009) . (2009) . – 166. n – Vasc 3ln-hi UAi adortcin469 cardioprotection in PUFA long-chain -3 755. 47 , 1.MieikJ lsiaP ice JP Vincken P, Plastina J, Meijerink 110. 0.AansoolsD aicC odJ Wood C, Rakiec D, Anagnostopoulos 109. 0.Yn ,FemnG rsnmotyS Krishnamoorthy G, Fredman R, Yang 108. 0.D J atA imrm A(93 akof Lack (1993) RA Riemersma & AM Dart XJ, Du S 107. Suzuki M, Nishigaki J, Kurihara 106. SL Song HJ, Ma Q, Li 105. 0.Cri ,RibwR,EatMA Ewart RD, Rainbow S, Currie 104. 0.DnRitrH,BrciG phfT Opthof G, Berecki HM, Ruijter Den 102. M Chung H, Jordan NR, Matthan 101. 0.L ,M J hn H Zhang HJ, Ma Q, Li 103. 0.Kyao V zahnoR,Mso LN Maslov RV, Uzhachenko AV, Krylatov 100. 9 rltvA,UdzeoaD,BrasaaNA Bernatskaya DS, Ugdyzhekova AV, Krylatov 99. 7 ey ,HcaiA&Ka A(2002) I NA Bernatova B, Khan Bacova J, & Radosinska 98. A Hichami A, Denys 97. , subjectto theCambridgeCore termsofuse,available at taoaie hw muoouaigefcsin between link Nutr new effects evidence a macrophages: for RAW264.7 docosahexaenoyl- immunomodulating and peritoneal DHA, mouse shows of ethanolamine, metabolite ethanolamide onsfrtetrahymena. com- for of class pounds new A tetrahymena. in N-acylethanolamines Identi ilChem Biol J taoaie(HA identi (DHEA) ethanolamide docosahexaenoyl with metabolomics functional Decoding -rcioollcrladaadmd oppositely sym- heart rat nerves. the anandamide pathetic from release norepinephrine and modulate 2-arachidonoylglycerol of augmentation and ventricular C930. I(to) rat of channels. in K(ATP) suppression channels a potassium myocytes: on anandamide ertasiso nrthearts. H886 2, sympathetic Pt rat on 3 fats in unsaturated neurotransmission dietary by modulation -eitdC(+ ees smdltdb anand- by modulated nuclei. cardiac 804 is isolated in release amide Ca(2+) R-mediated eai eiwadmt-nlsso h matof impact in the outcomes arrhythmia of selected models. on meta-analysis animal acids fatty and omega-3 review tematic 158 myocardium. rat on anandamide of effects n nirhtmcpoete fade ihin rich diet a Res of Cardiovasc properties antiarrhythmic and oaryhoei fet fcrnr clso and occlusion coronary mechanism. 133 of possible a effects reperfusion: arrhythmogenic resistance to myocardial improve cannabinoids Endogenous 20)Atvto ftp Icnaiodreceptors reperfusion. cannabinoid and occlusion Med II effects coronary arrhythmogenic type of to tolerance of myocardial improves Activation (2001) yetnieadhrdtr yetilcrdmcrats. hypertriglyceridemic Biochem Cell hereditary Mol spontaneously and acids-treated in hypertensive fatty expression omega-3 connexin-43 and and untreated activity NOS Myocardial aeMPkns nyeatvt nhmnT-cells. human in activity Biochem enzyme Cell modu- kinase acid MAP docosahexaenoic late and acid Eicosapentaenoic – 2022 , 122 , 811. 131 105 fi aino noanbnisadrelated and endocannabinoids of cation – 523 , ,1 – 124. 2029. – 10. – 286 – 232 H892. 525. 73 Metabolism aaeeJPharmacol J Japanese 31532 , 143 , 316 , 347 mJPy.Cl Physiol Cell Phys. J Am 163 , – – 148. – 325. tal et fi 31541. Protist holadin and oil sh – 54 173. 20)Electrophysiological (2009) . fi tal et 1557 , snvlbociesignals. bioactive novel es 161 o elCardiol Cell Mol J 21)Efcsof Effects (2012) . mJPhysiol J Am 452 , ulEpBo Meds Biol Exp Bull – tal et 1565. tal et 87 tal et fl tal et ammation. – ,93 20)Asys- A (2005) . rJPharmacol J Br ulEpBiol Exp Bull 465. tal et 20)IP(3) (2008) . tal et 21)The (2011) . tal et . tal et 20)Pro- (2007) . tal et – 302 96. (2001) . (2011) . (2010) . (2011) . C924 , fi (2002) . hoil. sh tal et rJ Br 265 Mol 45 – , , .